MoneyWorks4Me

Biocon informs about disclosure

18 Aug 2026 Evaluate
Biocon has informed that it enclosed Company Statement with respect to ‘Biocon Announces U.S. FDA Approval for Yesintek® (ustekinumab-kfce) Single-dose Prefilled Autoinjector’. The above information will also be available on the website of the Company at www.biocon.com

The above information is a part of company’s filings submitted to BSE.

Biocon Share Price

414.05 1.95 (0.47%)
21-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1900.90
Dr. Reddys Labs. 1175.00
Cipla 1426.20
Lupin 2193.00
Zydus Lifesciences 1120.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: